Key result
Most high-risk people with HIV fail to meet guideline LDL-C targets amid underused statin therapy.
Cohort
Answers are grounded in this paper and cite their sources.
There is a significant gap in the utilization of lipid-lowering therapy and achievement of LDL-C targets among high-risk people living with HIV.
OBJECTIVES: evaluation of the DUALIS study aimed to examine cardiovascular risk and the achievement of low-density lipoprotein cholesterol (LDL-C) targets in a virologically suppressed cohort of people living with HIV in Germany. METHODS: Baseline cardiovascular risk was assessed using the European Society of Cardiology (ESC)-Systematic COronary Risk Evaluation 2 (SCORE2)/SCORE2-Older Persons (OP) and the current ESC guideline-recommended LDL-C targets among participants aged ≥40 years in the DUALIS study. Risk categorization was based on the ESC-SCORE2/SCORE2-OP results and the presence of specific comorbidities indicative of high risk and very high risk of CVD. Participants were enrolled between July 2015 and June 2017. CONCLUSIONS: The achievement of guideline-recommended LDL-C targets was low in the high- and very high-CVD-risk groups in the DUALIS study, reflecting low utilization of LLT in clinical practice.
No takes yet. Share an insight, caveat, or question.
Voit et al. (2025) conducted a cohort in HIV. Lipid-lowering therapy was evaluated on Achievement of guideline-recommended LDL-C targets (p=0.95). Guideline-recommended LDL-C target achievement was low in high- and very high-CVD-risk groups of people living with HIV, reflecting low utilization of lipid-lowering therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: